OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading
Niranjan Sudhakar, Larry Yan, Fadia Qiryaqos, et al.
Molecular Cancer Therapeutics (2024) Vol. 23, Iss. 10, pp. 1418-1430
Open Access | Times Cited: 6
Niranjan Sudhakar, Larry Yan, Fadia Qiryaqos, et al.
Molecular Cancer Therapeutics (2024) Vol. 23, Iss. 10, pp. 1418-1430
Open Access | Times Cited: 6
Showing 6 citing articles:
Elucidating the therapeutic potential of indazole derivative bindarit against K-ras receptor: An in-silico analysis using molecular dynamics exploration
Parmar Keshri Nandan, Sivaraman Jayanthi
Biochemistry and Biophysics Reports (2025) Vol. 41, pp. 101913-101913
Closed Access
Parmar Keshri Nandan, Sivaraman Jayanthi
Biochemistry and Biophysics Reports (2025) Vol. 41, pp. 101913-101913
Closed Access
Drugging the Undruggable and beyond: Emerging precision oncology approaches to target acquired resistance to KRAS G12C and KRAS G12D inhibitors
Ramesh R. Kale, Charudatt Samant, Krishnadas Nandakumar, et al.
Biochemical and Biophysical Research Communications (2025), pp. 151688-151688
Closed Access
Ramesh R. Kale, Charudatt Samant, Krishnadas Nandakumar, et al.
Biochemical and Biophysical Research Communications (2025), pp. 151688-151688
Closed Access
Precision peptide disruptors: The next generation of targeted therapeutics in oncology
Bria O'Gorman, Sean F. Cooke, Connor M. Blair
Cellular Signalling (2025), pp. 111783-111783
Open Access
Bria O'Gorman, Sean F. Cooke, Connor M. Blair
Cellular Signalling (2025), pp. 111783-111783
Open Access
A Phase Ia/b study of MEK1/2 inhibitor binimetinib with MET inhibitor crizotinib in patients with RAS mutant advanced colorectal cancer (MErCuRIC)
Francesca Aroldi, Elena Élez, Thierry André, et al.
BMC Cancer (2025) Vol. 25, Iss. 1
Open Access
Francesca Aroldi, Elena Élez, Thierry André, et al.
BMC Cancer (2025) Vol. 25, Iss. 1
Open Access
DLEU2 facilitates bladder cancer progression through miR-103a-2-5p/SOS1 axis
Yinlong Liu, Jian Hu, Baochun Liao, et al.
PeerJ (2025) Vol. 13, pp. e18995-e18995
Open Access
Yinlong Liu, Jian Hu, Baochun Liao, et al.
PeerJ (2025) Vol. 13, pp. e18995-e18995
Open Access
Targeting guanine nucleotide exchange factors for novel cancer drug discovery
Sahar F. Bannoura, Husain Yar Khan, Md. Hafiz Uddin, et al.
Expert Opinion on Drug Discovery (2024) Vol. 19, Iss. 8, pp. 949-959
Closed Access | Times Cited: 1
Sahar F. Bannoura, Husain Yar Khan, Md. Hafiz Uddin, et al.
Expert Opinion on Drug Discovery (2024) Vol. 19, Iss. 8, pp. 949-959
Closed Access | Times Cited: 1
Development and safety of investigational and approved drugs targeting the RAS function regulation in RAS mutant cancers
Jinjin Li, Wentong Wu, Jiajia Chen, et al.
Toxicological Sciences (2024) Vol. 202, Iss. 2, pp. 167-178
Closed Access
Jinjin Li, Wentong Wu, Jiajia Chen, et al.
Toxicological Sciences (2024) Vol. 202, Iss. 2, pp. 167-178
Closed Access
Mechanisms of Resistance to KRAS Inhibitors: Cancer Cells' Strategic Use of Normal Cellular Mechanisms to Adapt
Noritaka Tanaka, Hiromichi Ebi
Cancer Science (2024)
Open Access
Noritaka Tanaka, Hiromichi Ebi
Cancer Science (2024)
Open Access
